Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
03
2019
revised:
08
09
2019
accepted:
16
10
2019
entrez:
31
12
2019
pubmed:
31
12
2019
medline:
19
5
2020
Statut:
epublish
Résumé
Ovarian epithelial carcinoma (OEC) is the most frequent ovarian tumor, characterized by a high mortality in advanced stages where conventional therapies are not effective. Based on the role of the immune system in the progression of this disease, immunotherapy using checkpoint blockade has been considered as a therapeutic alternative. Nevertheless, its results do not match up to the positive results in entities like melanoma and other malignancies, suggesting the need to find other therapies to be used alone or in combination. Dendritic cell- (DC-) based vaccines have shown promising results in several types of cancer, such as melanoma, prostate, and lung cancers, due to the essential role played by DCs in the activation of specific T cells, thus using other ways of activating the immune response than immune checkpoint blockade. During the last decade, we have used DC-based vaccines loaded with an allogeneic heat shock-conditioned melanoma cell lysate in the treatment of advanced stage patients in a series of clinical trials. In these studies, 60% of treated patients showed immunological responses which correlated positively with improved survival. Considering the relevance of ovarian cancer and the promising results of our DC-based vaccine, we show here that heat shock-conditioned cell lysates derived from ovarian epithelial carcinoma cell lines have the potential to induce the phenotypic and functional maturation of human DC, which in turn, is able to induce an efficient CD4
Identifiants
pubmed: 31886313
doi: 10.1155/2019/9631515
pmc: PMC6899292
doi:
Substances chimiques
Antigens, Neoplasm
0
Cancer Vaccines
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9631515Informations de copyright
Copyright © 2019 Iván Flores et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Oncol Lett. 2017 Jul;14(1):776-786
pubmed: 28693233
Biomedicines. 2016 May 03;4(2):
pubmed: 28536377
Front Immunol. 2013 Dec 03;4:417
pubmed: 24348481
J Immunol Res. 2018 Mar 18;2018:3982942
pubmed: 29744371
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643231
Genome Med. 2018 Oct 31;10(1):81
pubmed: 30382883
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Am J Reprod Immunol. 2005 Dec;54(6):369-77
pubmed: 16305662
Cancer Res. 2009 Sep 15;69(18):7329-37
pubmed: 19738057
Hum Vaccin Immunother. 2014;10(11):3261-9
pubmed: 25625929
Br J Cancer. 2015 Mar 31;112 Suppl 1:S108-15
pubmed: 25734389
Nat Med. 2014 Dec;20(12):1458-63
pubmed: 25384086
Blood. 2000 Nov 1;96(9):3102-8
pubmed: 11049990
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S61-70
pubmed: 22443134
Semin Immunol. 2008 Oct;20(5):286-95
pubmed: 18951039
Curr Treat Options Oncol. 2017 Aug 24;18(10):59
pubmed: 28840453
Clin Exp Immunol. 2005 Dec;142(3):555-68
pubmed: 16297169
J Immunother. 2012 Feb-Mar;35(2):196-204
pubmed: 22306908
J Clin Oncol. 2009 Feb 20;27(6):945-52
pubmed: 19139436
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Br J Cancer. 2013 Sep 17;109(6):1488-97
pubmed: 23989944
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951
pubmed: 29093164
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
J Clin Invest. 2009 Aug;119(8):2231-44
pubmed: 19620771
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Clin Cancer Res. 2011 Apr 15;17(8):2474-83
pubmed: 21292818
Cancer Immunol Immunother. 2018 Dec;67(12):1897-1910
pubmed: 29600445
BMC Cancer. 2018 May 24;18(1):587
pubmed: 29793429
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
N Engl J Med. 2004 Dec 9;351(24):2519-29
pubmed: 15590954
Melanoma Res. 2012 Jun;22(3):263-70
pubmed: 22516968
J Immunol. 2000 Aug 1;165(3):1705-11
pubmed: 10903782
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Immunotherapy. 2016 Jun;8(7):821-37
pubmed: 27349981
J Exp Med. 2012 Mar 12;209(3):495-506
pubmed: 22351930
Cancer Res. 2008 Sep 15;68(18):7684-91
pubmed: 18768667
J Transl Med. 2013 Jun 18;11:149
pubmed: 23777306
J Immunotoxicol. 2012 Jul-Sep;9(3):241-7
pubmed: 22524673
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446